Patents by Inventor Eric Swayze

Eric Swayze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9567588
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 14, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Publication number: 20160068846
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Application
    Filed: September 15, 2015
    Publication date: March 10, 2016
    Applicant: ISIS PHARMACEUTICALS INC.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Publication number: 20140107180
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 17, 2014
    Applicant: ISIS PHARMACEUTICALS INC.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia
  • Patent number: 8143230
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: March 27, 2012
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
  • Patent number: 7943749
    Abstract: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2?-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: May 17, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Michael T. Migawa, Richard H. Griffey, Eric Swayze
  • Publication number: 20090306005
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: December 10, 2009
    Applicant: Isis Phamaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
  • Publication number: 20090203896
    Abstract: Compounds and compositions are provided for modulating the expression of survivin. The compounds, exemplified by those acting through an RNAi antisense mechanism of action, include double-stranded and single-stranded constructs, as well as siRNAs, canonical siRNAs, blunt-ended siRNAs and single-stranded antisense RNA compounds. Methods of using these compounds for modulation of survivin expression and for treatment of diseases associated with expression of survivin are provided.
    Type: Application
    Filed: April 27, 2009
    Publication date: August 13, 2009
    Inventors: Balkrishen Bhat, Bharvin Kumar Patel, Eric Swayze
  • Publication number: 20090203893
    Abstract: Antisense compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The antisense compounds exhibit enhanced anti-miRNA activity. Further provided are methods for enhancing the inhibitory activity of an antisense compound targeting a miRNA, comprising incorporating stability enhancing sugar modifications into the antisense compounds.
    Type: Application
    Filed: August 29, 2006
    Publication date: August 13, 2009
    Applicant: Regulus Therapeutics, LLC
    Inventors: Christine E. Esau, Eric Swayze
  • Patent number: 7541344
    Abstract: Compounds and compositions are provided for modulating the expression of survivin. The compounds, exemplified by those acting through an RNAi antisense mechanism of action, include double-stranded and single-stranded constructs, as well as siRNAs, canonical siRNAs, blunt-ended siRNAs and single-stranded antisense RNA compounds. Methods of using these compounds for modulation of survivin expression and for treatment of diseases associated with expression of survivin are provided.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: June 2, 2009
    Assignees: Eli Lilly and Company, ISIS Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Bharvin Kumar Patel, Eric Swayze
  • Publication number: 20080214845
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: February 29, 2008
    Publication date: September 4, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Xiaojing Wang, Eric Swayze, Richard H. Griffey
  • Publication number: 20080045468
    Abstract: The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2?-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Application
    Filed: April 27, 2007
    Publication date: February 21, 2008
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Stephen Hanessian, Janek Szychowski, Susanta Adhikari, Kandasamy Pachamuthu, Michael Migawa, Richard Griffey, Eric Swayze
  • Publication number: 20080039618
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modification comprising a polycyclic sugar surrogate. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a polycyclic sugar surrogate modification.
    Type: Application
    Filed: October 12, 2007
    Publication date: February 14, 2008
    Inventors: Charles Allerson, Balkrishen Bhat, Anne Eldrup, Muthiah Manoharan, Richard Griffey, Brenda Baker, Eric Swayze
  • Publication number: 20080015162
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: January 17, 2008
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett Monia, Punit Seth, Andrew Siwkowski, Eric Swayze, Edward Wancewicz
  • Publication number: 20070287831
    Abstract: The present invention provides 5?-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5?-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.
    Type: Application
    Filed: May 10, 2007
    Publication date: December 13, 2007
    Inventors: Punit Seth, Eric Swayze
  • Publication number: 20070275921
    Abstract: The present invention provides double stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading the opposite strand into the RISC (or cleavage) complex. In particular, the present invention provides oligomeric compounds that comprise chemical modifications in at least one of the strands to drive loading of the opposite strand into the RISC (or cleavage) complex. Such modifications can be used to increase potency of duplex constructs that have been modified to enhance stability. Examples of chemical modifications that drive loading of the second strand include, but are not limited to, MOE (2?-O(CH2)2OCH3), 2?-O-methyl, -ethyl, -propyl, and —N-methylacetamide. Such modifications can be distributed throughout the strand, or placed at the 5? and/or 3? ends to make a gapmer motif on the sense strand. The activity of the 4?-thio gapmer RNA antisense strand can be improved by incorporating alternating MOE or MOE gapmer motif into the sense strand.
    Type: Application
    Filed: June 2, 2005
    Publication date: November 29, 2007
    Inventors: Eric Swayze, Balkrishen Bhat, Richard Griffey, Thazha Prakash, Charles Allerson
  • Publication number: 20070249049
    Abstract: The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Application
    Filed: January 27, 2007
    Publication date: October 25, 2007
    Inventors: Eric Swayze, Punit Seth
  • Publication number: 20070185047
    Abstract: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 9, 2007
    Inventors: Balkrishen Bhat, Thazha Prakash, Prasad Dande, Charles Allerson, Richard Griffey, Eric Swayze
  • Publication number: 20070185046
    Abstract: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 9, 2007
    Inventors: Balkrishen Bhat, Thazha Prakash, Prasad Dande, Charles Allerson, Richard Griffey, Eric Swayze
  • Publication number: 20070179106
    Abstract: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif, a fully modified motif, a positionally modified motif or an alternating motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In some embodiments, the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: December 1, 2006
    Publication date: August 2, 2007
    Inventors: Balkrishen Bhat, Thazha Prakash, Prasad Dande, Charles Allerson, Richard Griffey, Eric Swayze
  • Patent number: RE48461
    Abstract: Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: March 9, 2021
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Robert A. Macleod, Youngsoo Kim, Tianyuan Zhou, Susan M. Freier, Punit Seth, Eric Swayze, Brett Monia